UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: November 13, 2026
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into
English)
Stanislas Veillet
Biophytis S.A.
Silver Innov
54 rue Molière
94200 Ivry sur Seine, France
+33 1 76 28 40 83
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨
Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On November 12, 2026, Biophytis S.A. issued
a press release announcing that the ordinary and extraordinary general meeting convened for November 12, 2026, was unable to validly
deliberate due to the lack of a quorum and that, in accordance with the law, the meeting is therefore reconvened, with the same agenda,
on Friday, November 27, 2026, at 2:00 p.m. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT LIST
| Exhibit | |
Description |
| | 99.1 | |
Press Release dated November 12, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
BIOPHYTIS S.A. |
| |
|
|
| Date: November 13,
2026 |
By: |
/s/ Stanislas Veillet |
| |
|
Name: Stanislas Veillet |
| |
|
Title: Chairman and Chief Executive
Officer |
Exhibit 99.1
General Meeting of November 12, 2026:
Quorum Not Met
Notice of a second General Meeting on November 27,
2026
Paris (France) and Cambridge (Massachusetts,
United States), November 13, 2026, at 7:00 a.m. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis”
or the “Company”), informs its shareholders that the ordinary and extraordinary general meeting convened for
November 12, 2026, at 2:00 p.m. was unable to validly deliberate due to the lack of a quorum. Shareholders present, represented,
or voting remotely or by mail accounted for 12.46% of the share capital, while the required quorum was 20% for the ordinary portion and
25% for the extraordinary portion.
In accordance with the law, the meeting is therefore
reconvened, with the same agenda, on Friday, November 27, 2026, at 2:00 p.m., at the Silver Innov Building,
54 rue Molière, 94200 Ivry-sur-Seine. The notice of the second meeting will be published in the BALO on November 16, 2026.
What Changes with the Second Notice
| · | Ordinary session (including approval of
the financial statements for fiscal year 2025): no quorum is required. |
| · | Extraordinary session: Shareholders present,
represented, or voting remotely must hold at least one-fifth (20%) of the voting shares. |
| · | Votes Already Cast: Mail-in ballots, proxies,
and admission cards received for the first meeting remain valid for the second meeting. Shareholders who have not yet voted are invited
to do so as soon as possible, in accordance with the procedures outlined in the notice of meeting. |
Consideration of appointing an ad hoc representative
to represent absent shareholders at the general meeting
Given the low turnout observed, the Company intends
to request that the President of the Paris Commercial Court appoint an ad hoc proxy to represent absent shareholders at the meeting on
November 27, 2026, and to exercise the voting rights attached to the shares of absent shareholders.
This measure is intended to enable the meeting
to reach the required quorum and to deliberate on the proposed resolutions, including those under the extraordinary portion of the agenda.
To ensure complete neutrality in the voting results,
this proxy would split their votes between “for” and “against” according to predefined rules. This appointment
is subject to the sole discretion of the President of the Paris Commercial Court.
The Company will keep its shareholders informed
of any significant developments. Documents relating to the meeting are available on its website under the “General
Meetings” section.
***
About Biophytis
Biophytis SA is a clinical-stage biotechnology
company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate,
is a small molecule currently in development for muscular disorders (sarcopenia, Phase 3 ready to begin, and Duchenne muscular dystrophy,
Phase 1-2 to begin), respiratory (COVID-19, Phase 2-3 completed), and metabolic diseases (obesity, Phase 2 to begin). The company is headquartered
in Paris, France, with subsidiaries in Cambridge, Massachusetts, in the United States, and in Brazil. The Company’s common stock
is listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADSs (American Depositary Shares) are listed on the OTC market (BPTSY
- US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements.
Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking
statements by the use of words such as "outlook," "believes," "expects," "potential," "continues,"
"may," "will," "should," "could," "seeks," "predicts," "intends,"
"trends," "plans," "estimates," "anticipates," or the negative forms of these words or other comparable
terms. These forward-looking statements are based on assumptions that Biophytis considers reasonable. However, there can be no assurance
that the statements contained in these forward-looking statements will prove to be accurate, as they are subject to various risks and
uncertainties. The forward-looking statements contained in this press release are also subject to risks that are not yet known to Biophytis
or that are not currently considered material by Biophytis. Consequently, there are or will be significant factors that could cause actual
results to differ materially from those indicated in these statements. Please also refer to the section titled “Risks and Uncertainties
Facing the Company” in the company’s 2023 Annual Financial Report, available on the BIOPHYTIS website (www.biophytis.com)
and as set forth in the “Risk Factors” section of Form 20-F and other forms filed with the SEC (Securities and Exchange
Commission, USA). We do not undertake to publicly update or revise any forward-looking statements, whether as a result of new information,
developments, or otherwise, unless required by law.
Biophytis Contact
Investor Relations
investors@biophytis.com
Media Contact
Antoine Denry:antoine.denry@taddeo.fr –
+33 6 18 07 83 27
Nizar Berrada:nizar.berrada@taddeo.fr –
+33 6 38 31 90 50